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A newly available dataset on pharmaceuticals used in Scottish hospitals enabled an 
Environmental Risk Assessment that includes hospital consumption of pharmaceuticals, as previous 
UK rankings have been based on community prescription only. As health and the environment are 
devolved issues for the Scottish government, it is in any case merited to consider a Scottish ranking 
separately; regional differentiation is particularly relevant in the spatial context of the Water 
Framework Directive.  
Nine pharmaceuticals are identified as having a risk quotient (RQ) greater than 1. Four of 
these, the antibacterials  piperacillin , tazobactam, flucloxacillin and ciprofloxacin, had high hospital 
contributions and had not been highlighted before in rankings based on community prescriptions. 
Some drugs with RQ < 0.1 are almost exclusively used in hospitals and could be more concentrated 
near effluents carrying hospital wastewater, where they may be of local concern. As separate 
treatment of hospital effluents is a policy option, specific inclusion of hospital consumption is 
important. Continually increasing availability of ecotoxicological data and trends in consumption 
further contribute to a substantially different prioritisation than in previous rankings.  This leads us 
to conclude that regular review of risk is necessary.  
 




Pharmaceutical micro-pollutants in aquatic environments and their environmental effects 
are receiving increasing attention from government institutions [1], academic researchers [e.g. 2, 3] 
and the popular press [4]. Recently, the European Commission placed 3 pharmaceuticals – the 
analgesic diclofenac and the hormones estrone (E1) and 17ß ethinyl estradiol (EE2) – on a “watch 
list” to gather monitoring data for the purpose of supporting the determination of appropriate 
measures to address the risk posed by those substances [1]. Pharmaceutical products are used 
ubiquitously in hospitals and in the community. Following human consumption, excreted residue 
enters the sewer either as the original parent compound or metabolite and is only partially removed 
in wastewater treatment works [5]. The continuous input of sewage effluent into surface waters 
leads to chronic exposure of aquatic organisms and toxic effects can occur at environmentally 
relevant concentrations [3, 6].  
 
As thousands of different pharmaceutically active compounds are on the market - 
approximately 3000 are licensed in the UK [7] - screening is useful to gauge which pose the greatest 
environmental risk and might therefore warrant a more detailed risk assessment or environmental 
sampling and monitoring.  In order to decide on approaches and strategies for the reduction of 
pharmaceuticals in the environment, an understanding of sources is vital. Advanced wastewater 
treatment technologies are available to remove some pharmaceutical residue [8], but can be 
expensive and energy intensive [9]. In some situations, point source treatment at hospitals could be 
merited [10]. Data on the range, relative amounts and toxicities of medicines used in hospitals and 
the community can inform decisions on whether and where advanced treatment is appropriate; 
these decisions will almost certainly need to be country- or region specific.  
 
Prescription data can be used as a starting point for the identification of nationally relevant 
drugs, such as in Ayscough’s screening exercise for the UK Environment Agency [7], but many 
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previous studies are limited by their adopted method or available datasets for ranking. The UK 
National Health Service (NHS) stores data on drugs dispensed in the community separately from 
data on drugs dispensed in hospitals. Previous studies on environmental risk from pharmaceuticals 
in the UK [11, 12, 13] were based on community prescription data only, excluding hospital 
consumption.  Webb [14] included hospital consumption but limited his assessment to 60 
compounds for which ecotoxicity data were available at the time. A further barrier to complete 
assessment of pharmaceutical consumption is, as remarked by Ayscough et al. [7] as well as 
Sebastine and Wakeman [12], that detailed data for over-the-counter (OTC) sales of drugs are not 
readily available for the UK.  
 
Studies from elsewhere in the EU report that an estimated 20-25% (by total weight) of all 
human medicine is used in hospitals [15, 16], but the contribution from hospitals varies per drug. In 
Germany, the hospital contribution for total antibacterials does not exceed 25%, with 
cephalosporins and to a lesser extent penicillins showing a relatively high hospital contribution [17]. 
For iodinated contrast media (ICM) it is estimated to be approximately 50% [18]; hospital 
consumption of the cytostatics is also relatively high. Weissbrodt et al. [16] note that 70% of 
cytostatics and 50% of ICM consumed in hospitals are administered to outpatients and therefore 
likely to be excreted in the community. Drugs dispensed to inpatients may also be excreted after the 
patients are discharged from hospital. 
 
Several studies have measured the contribution to pharmaceutical load made by hospitals. 
Ort et al. measured residues in WWTP and hospital wastewater and found low (<15%) hospital 
contributions for all drugs apart from trimethoprim and roxithromycin [19]. However, in rural areas 
with no large population centres, large hospitals with a full range of treatment facilities may be 
encountered in smaller towns, where they will serve a population much greater than that of the 
town where the hospital is located [9]. Other studies investigating hospital contributions at specific 
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wastewater treatment plants confirm that in some situations hospitals contribute very significantly 
to overall pharmaceutical load at WWTP: Escher et al.[20] show this using predictive data, Santos et 
al. [21] and Verlicchi et al.[22] using measured values. Santos et al. [21] found particularly high 
hospital contributions to loads for receptor antagonists, antibacterials and analgesics, whereas 
Verlicchi et al. [22] found high contributions for antibacterials, receptor antagonist and lipid 
regulators. Ort et al. [23] demonstrated that inadequate sampling regimes for hospital wastewater 
can pose significant uncertainties for the results; using a predictive approach such as in the present 
study can help identify such uncertainties, e.g. by enabling checks that expected compounds are 
captured by the sampling process. Predictive data, on the other hand, do not identify strong 
fluctuations and instead result in average values. As concentrations in hospital effluents are more 
likely to show such strong variations than community effluents, in the present study, some drugs are 
highlighted specifically because of their high hospital contribution, which points towards temporal 
fluctuations and an uneven spatial distribution with potential ‘hotspots’ of residue near effluents 
containing hospital wastewater.  
 
Since Jones et al. [13] carried out their ranking exercise in 2002, a dataset for hospital 
consumption in Scotland has become available. Combined with a dataset on pharmaceuticals 
dispensed in the community, this enabled us - for the first time in the UK - to prioritise drugs by 
environmental risk, based on consumption data inclusive of pharmaceuticals used in hospitals. 
Because the hospital consumption data covered Scottish hospitals only, the screening exercise was 
carried out specifically for Scotland. The research methodology is suitable for application in other 
national or regional contexts.  
 
METHODOLOGY 
Data sources, calculation of total consumption and hospital contribution 
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Data on pharmaceutical use in the community were purchased from the Scottish National 
Health Service’s Information Services Division (NHS ISD; data derived from the NHS Prescribing 
Information System) for the top 250 prescribed drug products by quantity (i.e. number of items 
dispensed) (NHS prescriptions only) for the period April 2010 – March 2011. Hospital consumption 
data were obtained for the same period of all medicines dispensed in hospitals in Scotland from the 
Hospital Medicines Utilisation Data (HMUD) database. X-ray contrast media were not included in the 
database. As for the community data, the active ingredients of the top 250 products by quantity 
used in hospitals were selected and summed by compound. In accordance with the ‘Guideline on the 
Environmental Risk Assessment of Pharmaceutical Products for Human Use’, published by the 
European Medicines Agency (EMEA) in 2006 [24], vitamins, electrolytes, amino acids, peptides, 
proteins, carbohydrates, lipids, vaccines and herbal medicinal products were excluded from analysis. 
In addition, emollients and barrier preparations (section 13.2 of the British National Formulary, a 
joint publication by the Royal Pharmaceutical Society and the British Medical Association) were 
excluded; these are often prescribed in very large quantities and would have dominated the 
consumption data. Emollients and barrier preparations mostly consist of paraffin and other fatty 
substances, but can contain antimicrobials such as chlorhexidine gluconate. It is acknowledged that 
antimicrobials from community consumption are therefore underestimated by the present study; 
the exclusion was necessary for budgetary reasons and was thought to be preferable to 
overrepresentation of this group in the data. It is recommended that antimicrobials should be 
investigated elsewhere in full, taking also into account their extensive use in OTC products. 
 
The current summation of the mass of active compounds in the top 250 products yielded 
total mass for 165 different compounds. 51 drugs only occurred in the community data, 41 only in 




hi  = the percentage of total dispensed compound i which is dispensed in hospitals 
Ai,h  = the total amount of compound i dispensed in hospitals 
Ai,c = the total amount of compound i dispensed in the community. 
It was assumed that all dispensed pharmaceuticals are consumed. A recent survey by Healthcare 
Without Harm [25] indicated that most unwanted pharmaceuticals are disposed of via municipal 
solid waste, in which case our assumption would result in an overestimation of concentrations in 
WWTP effluent; however, where pharmaceuticals are disposed via the toilet or sink (or vomited up), 
the amount of active ingredient that enters the environment can be higher than when they are 
consumed. Specific data on disposal behaviours in hospitals vs. in the community could not be 
found.  
 
Ranking of pharmaceuticals by risk to the aquatic environment in Scotland  
The approach for risk assessment was developed with reference to the aforementioned EU 
Technical Guidance Document (EU TGD) on Environmental Risk Assessment Part II [26] and the 
EMEA guideline [24], which define the potential environmental risk of a substance as a Risk Quotient 
(RQ) RQ = PEC
PNEC
            (2) 
whereby  
RQ  = the Risk Quotient 
PEC  = the Predicted Environmental Concentration and  
PNEC = the Predicted No Effect Concentration. 
The predicted environmental concentration is calculated in the first instance as PEC(unrefined) w,i = Ai,c+Ai,h ((365∗P∗Vc)+Vh)∗D         (3) 
whereby 
 PECw,i  = the expected concentration of compound i  in surface water  
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Ai,c  = the amount of compound i used per year in the community; 
Ai,c  = the amount of compound i used per year in hospitals; 
P  = the population under consideration; 
Vc = the amount of wastewater produced by 1 person per day; 
Vh = the total amount of hospital wastewater in 1 year in Scotland  
D  = a dilution factor in the environment; 
Based on Scottish Government statistics [27] a population P of 5.222 million was assumed 
for Scotland for 2010, and water consumption per person per day Vc assumed as 150 litres. Water 
consumption in Scottish hospitals in the year April 2009- March 2010 was 5,163,989 x103 L [28].  A 
standard dilution factor of 10 is used, conform the Technical Guidance Document. It should be noted 
that under low flow conditions (Q95) such a dilution is not available everywhere. Available dilution 
under Q95 conditions was calculated for 15 Scottish WWTP in the Chemicals Investigation 
Programme carried out by UK Water Industries Research (UKWIR) and ranged from 1.9 to 590 [A. 
Zyndul, Scottish Water, Scotland, personal communication]. This does not affect the order of our 
ranking but again points to the need for spatial differentiation in risk assessments. The number of 
locations where concentrations exceed targets is of crucial importance to the affordability of 
strategies to address such exceedances. 
 
The EMEA guideline stipulates that if PECunrefined is below 0.01 µg/l, and no other 
environmental concerns are apparent, the product is unlikely to represent a risk to the environment 
[24]. After our initial assessment, 31 compounds with PEC(unrefined)w,i < 0.01 µg/l were omitted from 
further quantitative analysis.  Levonorgestrel and ethinyl estradiol were found to have a PEC < 0.01 
µg/l, but as very low PNECs (< 0.0001 µg/l) are known for these compounds, they were therefore 




PNEC values were sought for all compounds with a PECunrefined > 0.01 µg/l and levonorgestrel 
and ethinyl estradiol either directly from literature, or by calculation from experimental data in 
literature, or by modelling using the Structure-Activity Relationship modelling software ECOSAR. In 
the case of 4 drugs, PNEC data were taken from Kümmerer and Henningen’s study on ‘Promoting 
resistance by the emission of antibacterials from hospitals and households into effluent’ [29]. In the 
study, PNECs are calculated as Minimum Inhibitory Concentration (MIC50) divided by 10, which the 
authors state is a somewhat arbitrary but good compromise for risk assessment. It is acknowledged 
that these different derivations of PNEC introduce an element of uncertainty in the resulting ranking 
and where further experimental data become available in the future they should replace ECOSAR 
values.  
 
For compounds with 
PEC(unrefined)w,i 
PNEC
 > 0.1, PEC(unrefined) w,i was refined by including data on 
excretion and removal in wastewater treatment with activated sludge: 
PECw,i = (Ai,c+Ai,h)∗η�1− R100�365∗P∗V∗D           (4) 
whereby 
R  = the removal efficiency in wastewater treatment (R in %) 
η = percentage excreted as unchanged parent compound (0 < η < 1).   
Data on percentage excreted as parent compound were mostly taken from Ashley and Currie [30]. 
The body of research into removal of pharmaceuticals was reviewed and presented in several 
studies, most comprehensively in Verlicchi et al. [5]. Removal efficiencies are not available for all 
compounds and, where they are, there is considerable variation in the values reported. It should be 
noted that combined sewers are common in Scotland and that therefore sewage may enter the 






Based on the available data, for 43 drugs the hospital contribution was 100% (note that this 
indicates that the compound was not present in the top 250 community prescribed products, rather 
than that it is used exclusively in hospitals (although this may be the case), and vice versa). Of these, 
24 had a PECunrefined > 0.01 µg/l and were therefore investigated further.  High (> 20%) hospital 
contributions were found in particular for antibacterials: piperacillin  (4.5 tonnes (t) prescribed in 
hospitals; 100% hospital contribution) and tazobactam (0.5 t; 100%), which are normally 
administered together, metronidazole (0.3 t; 100%), clarithromycin (0.1 t; 100%), ciprofloxacin (3.4 t; 
26%), flucloxacillin (1.4 t; 22%), and several others in smaller quantities. In other therapeutic groups, 
hyperkalaemia drug calcium polystyrene sulphonate (0.7 t; 100%), cancer drugs capecitabine (0.5 t; 
100%) and hydroxycarbamide (0.3 t; 100%), antipsychotic medicine clozapine (0.4 t; 100%), angina 
medication glyceryl trinitrate (0.3 t; 100%), enzyme inhibitor clavulanic acid (used in the combination 
drug co-amoxiclav) (0.2 t;100%), hepatitis C drug ribavirin (0.2 t; 100%), antivirals aciclovir (0.2 t; 
100%), and lopinavir (0.1 t; 100%), gastric ulcer medicine sucralfate (0.1 t; 100% and schizophrenia 
drug amisulpride (0.1 t; 100%), sleeping tablet trazodone (0.5 t; 66%), asthma drug salbutamol (0.3 t; 
33%) and a number of others used in smaller quantities also have high hospital contributions.  
 
Attention is also drawn to 2  antiseptic substances: the surgical scrub povidone-iodine and 
chlorhexidine gluconate, used amongst other things in mouthwash, as well as dimeticone, used in 
headlice shampoo. None of these have received much attention in the literature from an 
environmental risk perspective; these compounds are perhaps not strictly speaking medicines but 
disinfectant and pesticide compounds. All three are available under a General Sales License and, in 
addition to the amount prescribed, are therefore sold over the counter. The data suggest that the 
amount consumed in hospitals alone merits further analysis. It should be noted that the hospital 
contribution of chlorhexidine gluconate could not be calculated accurately due to the exclusion from 
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the community data (as mentioned in the methodology) and that its total consumption is 
underestimated.  
 
Ranking by mass 
Of the considered compounds, paracetamol is prescribed in the highest amount overall, with 
over 328 t prescribed in 2010. Three other analgesics, ibuprofen, aspirin and codeine, are also all in 
the top 10 prescribed compounds. Very high consumption is also reported for lactulose (201 t), a 
synthetic laxative, and for metformin hydrochloride (67 t), a diabetes medicine. The most consumed 
antibacterial is amoxicillin (13 t), followed by flucloxacillin (6 t).   
 
Overall risk assessment 
For the 131 with PECunrefined > 0.01 µg/l as well as ethinyl estradiol and levonorgestrel all data 
are given in the Supplementary Information (S.I.). Robust experimental-based PNEC values were 
found for 82 compounds. A further 41 values were obtained using EcoSAR modelling (or taken from 
literature referring to modelling). No PNEC, and therefore no RQ, could be found or calculated for 15 
compounds:  these are, in order of descending PEC: mesalazine, chlorhexidine gluconate, ferrous 
fumarate, calcium polystyrene, esomeprazole, dimeticone, glyceryl trinitrate, hydroxicarbamide, 
sodium feredetate, sucralfate, hyoscine butylbromide, montelukast, chlorphenamine, isotrenitoin, 
solifenacin, and tolterodine.  
 
It should be noted that the PEC values, and consequently all calculated RQ values, are based 
on the assumption of standard dilution of 10. Where less dilution is available, RQ values for 
individual compounds may be higher and vice versa. Not yet accounting for excretion and removal, 
53 pharmaceuticals were found to have a PECunrefined/PNEC greater than or equal to 0.1. Removal 
efficiency data was available for just under half of these 53 compounds. For the remaining 
compounds, a removal efficiency of 0% was assumed as a precautionary approach. This does of 
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course present an uncertainty in the ranking and lack of data is indicated in Table 1 and the S.I. 
Similarly, for 1 compound no excretion rate was found and excretion was assumed to be 100%.  
14 
 








































































































































Amoxicillin 13,277 12 96 80 0.15 0.0037 39  588.02   
Piperacillin 4,475 100 0c 80 1.2    0.06 21    
Flucloxacillin 6,278 22 0c 40 0.86 0.3 2.9    
Phenoxymethyl penicillin 
(Penicillin V) 3,406 10 60 60 0.28 0.1 2.8 0.004   
Tazobactam 559 100 0c 80 0.15    0.06 2.6    
Erythromycin 2,086 0 26 8 0.042 0.02 2.1 0.04 x <0.17 
Ketoconazole 180 0 0c 100d 0.062 0.05 1.2    
Ciprofloxacin 1,319 26 70 40 0.054 0.05 1.1    
Oxytetracycline 3,212 0 44 35 0.22 0.207 1.0 3.6  26.8 
Propranolol 1,020 0 39 2 0.0043 0.005 0.85  x 1.16 
Clotrimazole 52 11 31 95 0.012 0.014 0.84  x  
Naproxen 4,671 0 73 94 0.41 0.64 0.64 0.01  0.09 
Amlodipine 467 1 0c 8 0.013 0.28 0.57    
Venlafaxine 323 0 0c 5 0.0056 0.013 0.43    
Metformin 67,132 1 0c 100 23 60 0.38 0.01  0.19 
Ethinyl estradiol 1 6 78 9 9.8 x 10-6 0.00003 0.33   <0.01 
Povidone-Iodine 3,255 100 0c 50 0.56 1.84 0.30    
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Ferrous sulphate 4,697 9 0c 100d 1.6 7.1 0.23 0.16   
Allopurinol 3,123 0 0c 8 0.086 0.45 0.19 0.01   
Fluoxetine 683 1 56 8 0.0083 0.05 0.17  x 14.19 
Clopidogrel 1,173 7 0c 50 0.20 1.6 0.13    
Clarithromycin 98 100 0c 20 0.0067 0.07 0.096    
Gentamicin 40 100 0c 90 0.012 0.15 0.083    
Carbamazepine 4,909 0 18 2 0.028 0.42 0.066 0.19   
Ezetimibe 96 0 0c 20 0.0066 0.13 0.051    
Ranitidine 4,645 5 52 38 0.29 6.2 0.047   0.02 
a) A full dataset including all references for removal efficiency, excretion and PNEC are given in the Supplementary Information 2 
b) The number of decimals given is determined by the source publication 3 
c) Indicates no removal data; no removal assumed 4 
d) Indicates no excretion data; 100% excretion assumed 5 
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Thus refined, 9 drugs had an RQ > 1 (Table 1) and pose a significant risk to the environment; all but 1 
of these are antibacterials.  Ketoconazole (RQ 1.24) is an antifungal compound. RQ is highest for 
amoxicillin at 39, despite a removal efficiency of 96%.  This is due to a combination of high 
consumption and a low PNEC value. No removal efficiency was found for the hospital antibacterial 
piperacillin so that no removal in WWTP was assumed. As a result, the overall RQ value of 21 is likely 
to be an overestimation, but as this drug is likely to be unevenly distributed even a high degree of 
removal could locally give an RQ > 1. It must be noted that for piperacillin, flucloxacillin, 
phenoxymethylpenicillin and tazobactam, PNEC values, taken from Kümmerer and Henninger [29], 
were based on MIC values rather than experimental PNECs. In several other publications [e.g. 5, 32] 
such values are used alongside ecotoxicity data, but as described in section 2.2.2, their derivation is 
different and further research on the correlation between ecotoxicity data and MIC values is 
recommended.  
 
In the range 0.1 < RQ < 1, a wider range of therapeutic groups feature; the highest ranking 
drug other than antibacterials is the beta-blocker propranolol at 0.85, which is toxic at very low 
concentrations. The antifungal clotrimazole has an RQ of 0.84 but, as it is also available over the 
counter, consumption may be higher. However, as this compound is often used in a cream, it is also 
possible that unfinished tubes are disposed of with solid waste and do not enter the wastewater. 
Again, further research is recommended. Other featured compounds are the painkiller naproxen, 
the diabetes medicine metformin, the contraceptive hormone ethinyl estradiol, the anti-gout 
medication allopurinol, 2 antidepressants, an anti-thrombotic drug, 2 more antibacterials, an anti-
convulsant, a cholesterol absorption inhibitor, an antacid and a calcium channel blocker.  
 
A number of drugs with a calculated  0.001 < RQ < 0.1 have very high hospital 
concentrations. It may be prudent to pay some attention to these. Capecitabine  (RQ 0.03), 
metronidazole (RQ 0.02), lopinavir (RQ 0.02), clindamycin (RQ 0.01), amisulpride  (RQ 0.0035), 
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clozapine (RQ 0.0017) and fluticasone (RQ 0.0001) all have hospital contributions of 100% (based on 
the available data). Depending on the therapeutic group, these may be used in specific hospital 
types only; for example, amisulpride and clozapine arise mostly from the 22 mental hospitals in 
Scotland and will be concentrated around these localities. This could result in locally much higher 
risks than suggested by the overall RQ; it is suggested that for hospital drugs a different type of risk 
indicator may be required. This should be the subject of further research.  
 
DISCUSSION 
Comparison with measured values 
To validate predictions, we were able to compare the results of the UK Water Industries 
(UKWIR)’s Chemicals Investigation Programme (CIP) [31], in which 8 pharmaceuticals were 
monitored at 150 WWTP throughout the UK, with concentrations in effluent as predicted by the 
present study. For 7 out of 8 compounds, the 50th percentile values of measured concentrations in 
CIP are within a factor 5 of predictions. Four of these are above and 3 are below predicted values. 
Only the 50th percentile value for oxytetracycline is 12 times lower than the predicted value. 
Overestimation may be due to the assumption that all pharmaceuticals are consumed. 
Underestimation may be due to the fact that predictions were based on the assumption of removal 
in activated sludge, whereas at some facilities less efficient processes such as trickling filters are 
used for secondary treatment. 
 
Comparison with previous studies 
Where possible, results for RQ are compared with those presented in Jones et al. [13], who 
ranked the top 25 pharmaceuticals (by mass) in England by environmental risk, and Webb [14], also 
noting the compounds with ‘top 10’ PEC/PNEC ratios in Hilton et al.‘s prioritisation for monitoring 
for the Environment Agency [11]. In the latter, numerical values are not given although the authors 




Four of the drugs with RQ > 1, piperacillin, flucloxacillin, tazobactam and ciprofloxacin, have 
a hospital contribution greater than 20%; none of these was identified as of concern by Webb [14], 
Jones et al. [13], or Hilton et al. [11]. Penicillin V and erythromycin were previously listed as having a 
much lower RQ (below 0.1) by Jones et al. [13]. Amoxicillin was listed by Jones et al. [13] with an RQ 
of 588; this can be explained by the fact he assumed no metabolism or removal in sewage treatment 
works. Oxytetracycline had a higher RQ in rankings by Jones et al. [13] and Webb [14] than was 
found in the present study.  
 
Of the compounds with 0.1 < RQ < 1, propranolol, naproxen, metformin, and fluoxetine, 
were all previously identified as having an RQ > 0.1 by Webb [14], in accordance with our findings; 
Hilton et al. [11] previously identified  propranolol, clotrimazole, and fluoxetine as of concern.  Of 
the antimicrobials, apart from erythromycin, Hilton et al. highlighted trimethoprim and 
sulfamethoxazole [11]. The latter two are – according to the data at hand – not the ones posing the 
greatest risk in Scotland in terms of RQ. Comparison of the PNEC values given in Hilton’s study with 
those found for the ranking in the present study reveals that in the last decade, new toxicity data 
have become available for nearly all, resulting in higher risk quotients. An RQ > 0.1 for 
carbamazepine (0.07 in the present study) and ferrous sulphate (0.23 in the present study) had 
previously been identified by Jones et al. [13]. The authors also considered naproxen, allopurinol, 
and metformin but found RQ values much lower than found in the present study, as with increasing 
toxicity data the reported PNEC values have decreased by 2 orders of magnitude for most of these 
compounds. Venlafaxine, povidone-iodine, clopidogrel, clarithromycin, gentamicin, amlodipine and 
ezetimibe had not been identified by the studies we used for comparison. Of these, povidone-iodine, 
clarithromycin and gentamycin have very high hospital contributions, which would explain why they 
were not included by Jones et al. [13] or Hilton et al. [11] (although povidone-iodine may have been 




Comparison with other national studies 
Few other national studies were identified that considered both community and hospital 
consumption. Huschek et al.  [33] assessed environmental risks for pharmaceuticals in Germany in 
2004. Compounds with RQ > 1 were ciprofloxacin, clarithromycin, ethinylestradiol, acetylsalicylic 
acid (aspirin), paracetamol and povidone-iodine, whilst ibuprofen, metformin and bezafibrate had 
0.1 < RQ < 1. Several others, e.g. propranolol and carbamazepine, are listed as having lower RQs but 
would have had RQ > 1 if the PNECs found in the present study had been available.  Apart from 
bezafibrate, all of these identified by Huschek et al. were also identified with RQ > 0.1 in the present 
study. Huschek et al. did not identify some of our highest ranking compounds, e.g. piperacillin and 
flucloxacin, possibly because available toxicity data were limited or possibly because they fell below 
an initial cut-off point of sales in excess of 5000 kg/a. A study instigated by the Nordic Council of 
Ministers [34] investigated environmental risk from pharmaceuticals in the Nordic Countries. In 
Denmark, the following substances were identified: those with 0.01 < RQ < 0.1 were prednisolone, 
citalopram, metoprolol, tramadol and losartan; those with 0.1 < RQ < 1 were atorvastatin, 
norethisterone, felodipine, metformin, amlodipine, diazepam, and those with RQ > 1 sertraline, 
diclofenac, ibuprofen, and aspirin. There is a notable lack of antibacterial drugs on this list; this may 
be because the study only considered the top 40 most sold substances. Furthermore, the study uses 
‘defined daily doses’ (DDD) as defined by WHO for the calculation of the amount sold, which can be 
problematic in the case of combination drugs, such as co-amoxiclav or co-codamol, for which no 
DDD are issued. Hospital contributions in Denmark were much lower than those calculated in the 
present study; only prednisolone has a hospital contribution over 5%. In Finland, 65 compounds 
were considered, of which amlodipine, atorvastatin, and aspirin have 0.1 < RQ < 1. Metformin, 
paracetamol, ibuprofen, naproxen, and several sex hormones have RQ > 1. As in Denmark, no 




The comparison with these studies suggests that it is important to include a large number of 
substances for initial consideration, as some very low PNEC values can result in high risk even for 
compounds lower on a ranking by mass. There are a lot of similarities between the high ranking 
compounds in Huschek’s study and those in the present study; differences appear to be in some 
cases due to different PNEC data rather than actual different risks.   
 
Trends in consumption 
Changing consumption patterns are likely to affect risk assessment: the total number of 
antidepressant prescriptions in Scotland rose from 1.2M in 2003 to over 5M in 2012, whilst in the 
UK, gout, for which allopurinol can be prescribed, is reported to have risen by 64% between 1997 
and 2012 [35]. The prevalence of diabetes in Scotland, often treated with metformin, nearly doubled 
between 2003 and 2008 [36]. The use of antibacterial drugs continues to receive international 
attention because of concerns about resistance. The Scottish Antibacterial Prescribing Group (SAPG), 
established in 2008, has developed prescribing policies intending to influence the choice of 
antibacterial use towards narrower spectrum antibacterials, with a particular focus on co-amoxiclav, 
clindamycin, fluoroquinolones (mainly ciprofloxacin) and cephalosporins (‘the four C’s’) [37] and 
reports some interesting trends. In primary care (excluding dental), the use of broad spectrum 
penicillins (which include co-amoxiclav) and fluoroquinolones (which include ciprofloxacin) 
decreased by 6% and a dramatic 29%, respectively. In secondary care however, there was a 26% 
increase in the use of co-amoxiclav over the same period, whilst use of fluoroquinolones decreased 
by 8%. Use of the piperacillin-tazobactam combination increased by 30%. Use of macrolide 
antibacterials, which include erythromycin and clarithromycin, was relatively stable in both primary 
and secondary care (based on DDDs/1000/d). A drug not highlighted by the present study, 
nitrofurantoin, saw a doubling in use from 45.7 to 96.0 DDDs/1000/d. It is possible that where 
reduced use of certain antibacterials is encouraged, use of other antibacterials may increase as a 
result. Based on these trends, we may expect the hospital contributions for amoxicillin and for 
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ciprofloxacin to have increased, the RQ for ciprofloxacin and amoxicillin to have reduced slightly, and 
the RQ for piperacillin and tazobactam to have increased substantially since the data for the present 
study were collected. Given the ecotoxicological importance of antibacterial drugs, it would be 
highly interesting to investigate the environmental consequences of the rapidly developing 
antimicrobial resistance agenda more fully in a further study.  
 
Implications for mitigation 
Half of the pharmaceuticals with RQ > 1 have high hospital contributions, whilst a number of 
compounds with lower RQ may be locally concentrated WWTP serving hospitals and pose a local 
risk. In such situations, point source treatment of hospital effluent could be an effective strategy for 
the reduction of environmental risk as a large fraction of the pollutant load could be removed by 
treating a relatively small amount of wastewater. However, some pollutants of key concern, such as 
erythromycin and propranolol, would not be effectively targeted by point source treatment as they 
are predominantly used in the community. To enable informed decision making on treatment 
options, spatially differentiated risk assessment may be required to prioritise locations and select 
appropriate mitigation. The marked reduction in use in primary care of the four C’s indicates that 
where the necessary drivers are in place, pharmaceutical use can to some extent be influenced by 
prescribing policy, implying that such policies could be considered as a preventative measure to 
reduce environmental risk from pharmaceuticals. Other studies [25] indicate that disposal of waste 
pharmaceuticals via the sewer is still common despite collection facilities at pharmacies, so that 
awareness raising may be a useful intervention. No single obvious solution presents itself and it may 







CONCLUSIONS AND RECOMMENATIONS 
Attention is drawn to a number of drugs not previously highlighted as of concern for the UK. 
As expected, for some compounds this is likely due to the inclusion of the hospital consumption 
data; indeed 4 of these compounds – all with an RQ > 1 - have hospital contributions over 20%. 
However, several drugs not previously identified as of concern are predominantly used in the 
community. Three probable explanations are proposed. Firstly, in the past decade much more 
experimental ecotoxicity data have become available, in particular for antibacterials, which means 
lower PNEC values have been established. Based on the available datasets, antimicrobials now have 
the highest RQs. Secondly, compounds may previously have been excluded from research 
programmes due to the lack of analytical methods or due to other deliberate exclusions. Thirdly, for 
yet others a marked increase in consumption is thought to have led to an increased risk to the 
aquatic environment. The changes from previous prioritisations highlight the importance of regular 
review. 
 
As hospital drug usage and thus release into the environment is likely to have an uneven 
spatial distribution, risk quotients for hospital drugs may be locally higher than reported here. 
Geographical refinement of the risk assessment is recommended and should take account of any 
hospitals as well as local dilution rates. Although the available data on consumption, toxicity and 
removal are improving, gaps remain. For the newly highlighted drugs, it is recommended that 
further study on removal efficiencies as well as environmental studies are carried out. In order to 
make a complete, holistic risk assessment of the pharmaceuticals we consume, research is further 
required on the prevalence, fate and effect of active metabolites and the fate and effect of sorbed 
pharmaceutical residue and metabolites applied to land via sludge. Furthermore, as in previous 
studies, the datasets acquired were limited by both availability and price and required extensive and 
laborious manipulation before they could be used. Whilst the present study was able to identify a 
number of compounds over a range of treatment groups that carry a moderate or high 
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environmental risk for Scotland, it cannot exclude the possibility that others should also be of 
concern. As awareness of the issue of pharmaceuticals in the environment is growing and more 
regularly updated research is clearly required, it would be beneficial if data gathering and storage 
systems by NHS and other agencies were better suited also to the environmental types of analyses 
required. Interdisciplinary, multi-agency and international collaboration would be required to 
improve this situation.  
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[µg/l] RQ  
Reference RQs 
Jones Hilton Webb 
Mesalazine 6760 0 2.32 nd  0 * 100 * 2.32 nd 0 
  Ferrous fumarate 3540 6 1.22 nd  0 * 100 * 1.22 nd 
   Calcium polystyrene 
sulphonate 737 100 0.26 nd  0 * 100 1 0.26 nd 
   Esomeprazole 360 0 0.12 nd  0 * 0 2 0.00 nd 
   Dimeticone 354 24 0.12 nd  0 * 100 † 0.12 nd 
   Glyceryl trinitrate 331 100 0.12 nd  0 * 1 2 0.00 nd 
   Hydroxicarbamide 275 100 0.10 nd  0 * 50 2 0.05 nd 
   Sodium feredetate 225 9 0.08 nd  0 * 100 * 0.08 nd 
   Sucralfate 125 100 0.04 nd  0 * 4 2 0.00 nd 
   Hyoscine 
butylbromide 104 6 0.04 nd  0 * 2 2 0.00 nd 
   Montelukast 57.5 0 0.02 nd  0 * 0 2 0.00 nd 
   Chlorphenamine 35.5 9 0.01 nd  0 * 22 2 0.00 nd 
 
x 
 Isotrenitoin 23.9 100 0.01 nd  0 * 0 2 0.00 nd 
   Solifenacin 21.8 0 0.01 nd  0 * 7 3 0.00 nd 
   Tolterodine 16.6 0 0.01 nd  0 * 1 2 0.00 nd 
   Amoxicillin 13300 12 4.56 0.0037 4 96 4 80 5 0.15 3.9E+01 588.02 
  Piperacillin 4480 100 1.54 0.06 5 0 * 80 5 1.23 2.1E+01 
   Flucloxacillin 6280 22 2.16 0.3 5 0 * 40 5 0.86 2.9E+00 
   Phenoxymethyl 
penicillin (PCN V) 3410 10 1.17 0.1 5 60 4 60 5 0.28 2.8E+00 0.004 
  Tazobactam 559 100 0.19 0.06 6 0 * 80 1 0.15 2.6E+00 
   Erythromycin 2090 0 0.72 0.02 4 26 4 8 5 0.04 2.1E+00 0.04 x <0.17 
Ketoconazole 180 0 0.06 0.05 6 0 * 100 1 0.06 1.2E+00 
   Ciprofloxacin 1320 26 0.45 0.05 7 70 4 40 5 0.05 1.1E+00 
   Oxytetracycline 3210 0 1.10 0.207 4 44 4 35 2 0.22 1.0E+00 3.6 
 
26.8 
Propranolol 1020 0 0.35 0.005 9 39 4 2 10 0.00 8.5E-01 
 
x 1.16 
Clotrimazole 52.5 11 0.02 0.014 11 31 4 95 1 0.01 8.4E-01 
 
x 
 Naproxen 4670 0 1.60 0.64 12 73 4 94 13 0.41 6.4E-01 0.01 
 
0.09 
Amlodipine 467 1 0.16 0.28 14 0 * 8 10 0.01 5.7E-01 
   Venlafaxine 323 0 0.11 0.013 15 0 * 5 16 0.01 4.3E-01 
   Metformin 67100 1 23.06 60 17 0 * 100 18 23.06 3.8E-01 0.01 
 
0.19 
Ethinyl estradiol 1.44 6 0.00 0.00003 19 78 4 9 10 0.00 3.3E-01 
  
<0.01 
Povidone-Iodine 3260 100 1.12 1.84 17 0 * 50 †† 0.56 3.0E-01 
   Ferrous sulphate 4700 9 1.61 7.1 20 0 * 100 * 1.61 2.3E-01 0.16 
  Allopurinol 3120 0 1.07 0.45 12 0 * 8 10 0.09 1.9E-01 0.01 
  Fluoxetine 683 1 0.23 0.05 4 56 4 8 10 0.01 1.7E-01 
 
x 14.19 
Clopidogrel 1170 7 0.40 1.6 11 0 * 50 2 0.20 1.3E-01 
   Clarithromycin 97.9 100 0.03 0.07 4 0 * 20 5 0.01 9.6E-02 
   Gentamicin 40.2 100 0.01 0.15 5 0 * 90 5 0.01 8.3E-02 
   Carbamazepine 4910 0 1.69 0.42 21 18 4 2 22 0.03 6.6E-02 0.19 
  Ezetimibe 96.0 0 0.03 0.13 12 0 * 20 1 0.01 5.1E-02 
   Ranitidine 4650 5 1.60 6.2 9 52 4 38 10 0.29 4.7E-02 
  
0.02 
Trimethoprim 1060 12 0.37 3 23 40 4 60 5 0.13 4.4E-02 
 
x 
 Paracetamol 328000 6 
112.8
5 9.2 9 93 4 5 1 0.39 4.3E-02 1.29 x 
 Ibuprofen 16300 9 5.60 1.65 4 87 4 7 10 0.05 3.1E-02 0.99 x 
 Sulfasalazine 9760 0 3.35 30.3 E. -80 24 15 1 0.91 3.0E-02 0.04 
  Quinine 4210 0 1.44 10.1 25 0 * 20 1 0.29 2.9E-02 0.53 
 
0.54 
Capecitabine 504 100 0.17 0.2 9 0 * 3 1 0.01 2.6E-02 
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[µg/l] RQ  
Reference RQs 
Jones Hilton Webb 
Betahistine 
dihydrochloride 
165 0 0.06 2.3 E. 0 * 90 2 0.05 2.2E-02    
Metronidazole 301 100 0.10 1.25 5 38 4 40 5 0.03 2.0E-02   0.23 
Lopinavir 133 100 0.05 0.05 11 0 * 2 1 0.00 1.8E-02    
Phenytoin 456 1 0.16 0.5 E. 5 26 5 2 0.01 1.5E-02    
Clindamycin 55.5 100 0.02 0.5 5 0 * 35 5 0.01 1.3E-02    
Sertraline 791 0 0.27 0.056 12 0 * 0 1 0.00 9.7E-03    
Atenolol 3640 0 1.25 30 4 38 4 37 10 0.29 9.6E-03 0.01 x  
Simvastatin 4610 2 1.58 9.6 9 57 4 13 2 0.09 9.2E-03    
Losartan 1150 0 0.40 1.9 E. 0 * 4 1 0.02 8.3E-03   <0.01 
Orlistat 1110 0 0.38 1.92 9 0 * 4 2 0.02 7.9E-03    
Prednisolone 145 11 0.05 <2.3 27 0 * 30 1 0.01 6.5E-03    
Citalopram 988 1 0.34 6.5 E. 0 * 12 1 0.04 6.3E-03    
Tramadol  4820 4 1.65 64 25 23 4 30 28 0.38 6.0E-03  x <0.01 
Methadone 637 1 0.22 10.6 11 0 * 28 29 0.06 5.8E-03    
Gliclazide 3050 2 1.05 2 E. 0 * 1 1 0.01 5.2E-03    
Glipizide 28.7 0 0.01 0.24 E. 0 * 10 1 0.00 4.1E-03    
Lymecycline 2160 0 0.74 45.4 12 0 * 25 2 0.19 4.1E-03    
Amisulpride 109 100 0.04 5.4 E. 0 * 50 2 0.02 3.5E-03    
Hydroxychloroquine 
sulphate 
887 0 0.30 2.72 12 0 * 3 2 0.01 3.4E-03    
Benzydamine 
hydrochloride 
20.8 23 0.01 2.3 E. 0 * 100 † 0.01 3.1E-03    
Pravastatin 188 0 0.06 1.8 4 57 4 20 1 0.01 3.1E-03    
Magnesium 
hydroxide 
931 16 0.32 100 30 0 * 100 * 0.32 3.0E-03    
Omeprazole 2530 3 0.87 3 E. 9 4 1 2 0.01 2.6E-03   <0.01 
Metoclopramide 88.9 8 0.03 3.8 E. 0 * 30 2 0.01 2.4E-03    
Felodipine 30.6 0 0.01 0.05 9 0 * 1 1 0.00 2.1E-03    
Dihydrocodeine 
tartrate 
2740 3 0.94 108.9 E. 0 * 22 2 0.21 1.9E-03    
Clozapine 355 100 0.12 0.71 9 0 * 1 1 0.00 1.7E-03    
Mirtazapine 147 0 0.05 32 9 0 * 75 2 0.04 1.2E-03    
Fluticasone 72.1 100 0.02 0.48 25 0 * 2 31 0.00 1.0E-03   0.01 
Bisoprolol fumarate 169 1 0.06 35.6 9 0 * 55 10 0.03 9.0E-04    
Diclofenac 3180 4 1.09 9.7 4 29 4 1 10 0.01 8.0E-04 0.01 x  
Diazepam 171 3 0.06 2 4 14 4 3 10 0.00 7.6E-04   0.04 
Nicotine 42.0 0 0.01 2.4 E. 0 * 12 10 0.00 7.2E-04    
Rosuvastatin 66.2 0 0.02 1.8 9 0 * 5 2 0.00 6.3E-04    
Sodium valproate 3960 2 1.36 160 9 0 * 7 2 0.10 6.0E-04 0   
Loratadine 76.9 0 0.03 0.382 9 15 4 1 1 0.00 5.9E-04    
Doxazosin 69.9 0 0.02 2.3 9 0 * 5 2 0.00 5.2E-04    
Aspirin 11100 3 3.80 61 32 90 4 8 10 0.03 5.0E-04 0.01  1 
Baclofen 103 5 0.04 53.3 E. 0 * 70 2 0.02 4.6E-04    
Quetiapine 194 8 0.07 10 9 0 * 5 2 0.00 3.3E-04    
Salbutamol 814 34 0.28 240 19 61 4 64 2 0.07 2.9E-04    
Zopiclone 85.6 3 0.03 5.1 E. 0 * 5 2 0.00 2.9E-04    
Piroxicam 38.4 0 0.01 2.6 E. 0 * 5 2 0.00 2.5E-04    
Lansoprazole 1320 2 0.45 18 25 0 * 1 33 0.00 2.5E-04   <0.01 
Trazodone 835 66 0.29 14.2 E. 0 * 1 1 0.00 2.0E-04    
Chlorhexidine 
gluconate 
1490 83 0.51 2622 E. 0 * 100 † 0.51 1.9E-04    
Dipyridamole 3830 5 1.32 356 E. 0 * 5 2 0.07 1.9E-04    
Cetirizine 211 0 0.07 278 34 0 * 60 2 0.04 1.6E-04   <0.01 
Amitriptyline 1350 0 0.47 2.5 9 96 4 2 1 0.00 1.5E-04   1.29 
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Jones Hilton Webb 
Candesartan cilexetil 157 0 0.05 100 9 0 * 26 2 0.01 1.4E-04    
Betamethasone 15.1 0 0.01 1.9 9 0 * 5 2 0.00 1.4E-04    
Morphine 114 12 0.04 32 12 0 * 10 2 0.00 1.2E-04    
Bendroflumethiazide 234 1 0.08 26 E. 91 4 30 2 0.00 8.4E-05  x  
Clavulanic acid 202 100 0.07 332.7 E. 0 * 40 2 0.03 8.4E-05    
Prochlorperazine 48.3 0 0.02 2.4 E. 0 * 1 2 0.00 6.9E-05    
Cyclizine 44.1 100 0.02 2.5 E. 0 * 1 2 0.00 6.1E-05    
Ramipril 424 0 0.15 53 E. 0 * 2 2 0.00 5.5E-05    
Nitrazepam 27.4 0 0.01 9.5 E. 0 * 5 2 0.00 5.0E-05    
Lisinopril 617 0 0.21 4577 E. 0 * 90 2 0.19 4.2E-05    
Paroxetine 109 0 0.04 <2.5 9 91 4 2 1 0.00 3.6E-05   0.13 
Temazepam 84.2 5 0.03 17.4 E. 0 * 2 2 0.00 3.3E-05    
Azathioprine 286 0 0.10 59.3 E. 0 * 2 2 0.00 3.3E-05    
Nicorandil 343 2 0.12 56 E. 0 * 1 2 0.00 2.1E-05    
Loperamide 
hydrochloride 
21.4 4 0.01 52.3 9 0 * 10 2 0.00 1.4E-05    
Lamuvidine 72.4 100 0.02 320 9 >76 35 70 2 0.00 1.3E-05    
Enalapril maleate 207 0 0.07 346 19 69 4 20 10 0.00 1.3E-05    
Ribavirin 196 100 0.07 72 9 97 35 40 2 0.00 1.1E-05    
Lidocaine 66.4 100 0.02 106 9 0 * 5 10 0.00 1.1E-05    
Gabapentin 10800 4 3.70 24347.1 E. 93 4 100 2 0.26 1.1E-05   <0.01 
Perindopril 122 0 0.04 >990 34 0 * 12 2 0.01 5.1E-06   <0.01 
Aciclovir 151 100 0.05 200 9 97 35 5 36 0.00 3.9E-07    
Finasteride 42.8 0 0.01 20 34 0 * 0 2 0.00 3.7E-07   <0.01 
Carbocisteine 4320 8 1.48 100847
4 





E. 0 * 3 2 2.08 3.2E-07    
Hydrocortisone 51.6 0 0.02 565 E. 0 * 1 10 0.00 3.1E-07    
Isosorbide 
mononitrate 
707 0 0.24 75474 E. 0 * 2 2 0.00 6.4E-08    
Domperidone 209 13 0.07 12000 38 0 * 1 2 0.00 6.0E-08    
Aluminium hydroxide 1080 20 0.37 ∞ 30 0 * 100 * 0.37 0.0E+00    
Codeine 7440 4 2.56 0.06 E. 68 4 0 2 0.00 0.0E+00  x  
Mebeverine 
hydrochloride 
2500 0 0.86 27 E. 0 * 0 1 0.00 0.0E+00 0.74 x  
Levonorgestrel 3.51 9 0.00 <0.0000
8 
39 0 * 0 1 0.00 0.0E+00    
Warfarin 98.8 2 0.03 12 19 0 * 0 2 0.00 0.0E+00   <0.01 
Norethisterone 23.1 0 0.01 0.6 19 0 * 0 1 0.00 0.0E+00  x  
Atorvastatin 1860 0 0.64 0.13 12 0 * 0 2 0.00 0.0E+00    
Budesonide 25.7 100 0.01 8.6 9 0 * 0 2 0.00 0.0E+00   <0.19 
* Indicates lack of data, precautionary value used;     ** From [4], mean values were used;     † Not ingested;     †† Author's estimate;    u unrefined; 
E. Ecosar;     RQ = PEC/PNEC*Ecr*(1-R);     RQs from Jones et al. (2002), Hilton (2003) and Webb (2000) 	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